Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

Cancer Biology and Therapy

Volumn 14, Issue 4, 2013, Pages 347-356

  Gandhi, Nishant ^a   Wild, Aaron T ^a   Chettiar, Sivarajan T ^a   Aziz, Khaled ^a   Kato, Yoshinori ^b,c   Gajula, Rajendra P ^a   Williams, Russell D ^a   Cades, Jessica A ^a,b   Annadanam, Anvesh ^a   Song, Danny ^a,b   Zhang, Yonggang ^a   Hales, Russell K ^a   Herman, Joseph M ^a   Armour, Elwood ^a   DeWeese, Theodore L ^a,b   Schaeffer, Edward M ^a,b   Tran, Phuoc T ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

DNA damage response; Hsp90; NVP AUY922; Prostate cancer; Radiosensitizer

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUSE; NONHUMAN; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION;

DNA DAMAGE RESPONSE; HSP90; NVP-AUY922; PROSTATE CANCER; RADIOSENSITIZER;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; G2 PHASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RANDOM ALLOCATION; RESORCINOLS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875856412     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.23626     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, et al. Prostate cancer, Version 3.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10:1081-7; PMID:22956807.
3. Sandler HM, Mirhadi AJ. Radical radiotherapy for prostate cancer is the 'only way to go'. [Williston Park]. Oncology (Williston Park) 2009; 23:840-3; PMID:19839425.
4. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and shortterm androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365:107-18; PMID:21751904; http://dx.doi.org/10.1056/ NEJMoa1012348.
5. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26:2497-504; PMID:18413638; http://dx.doi.org/10.1200/JCO.2007.14.9021.
6. Bannuru RR, Dvorak T, Obadan N, Yu WW, Patel K, Chung M, et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: An updated systematic review. Ann Intern Med 2011; 155:171-8; PMID:21646550.
7. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009; 136:823-37; PMID:19269363; http://dx.doi.org/10.1016/j.cell.2009.02.024.
8. Pearl LH, Prodromou C. Structure and in vivo function of Hsp90. Curr Opin Struct Biol 2000; 10:46-51; PMID:10679459; http://dx.doi.org/10.1016/S0959- 440X(99)00047-0.
9. Pratt WB. The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998; 217:420-34; PMID:9521088.
10. Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006; 26(5A):3409-16; PMID:17094460.
11. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575-86; PMID:21575859; http://dx.doi.org/10.1016/j.ccr.2011.04.008.
12. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011; 10:2218-32; PMID:21623170; http://dx.doi.org/10.4161/cc.10.13. 16305.
13. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30:203-13; PMID:18439899; http://dx.doi.org/10.1016/j.molcel.2008.02. 024.
14. Surucu B, Bozulic L, Hynx D, Parcellier A, Hemmings BA. In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem 2008; 283:30025-33; PMID:18757368; http://dx.doi.org/10.1074/jbc.M803053200.
15. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270:24585-8; PMID:7592678; http://dx.doi.org/10.1074/jbc.270.41.24585.
16. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004; 10:8077-84; PMID:15585643; http://dx.doi.org/10.1158/1078-0432. CCR-04-1212.
17. Camphausen K, Tofilon PJ. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res 2007; 13:4326-30; PMID:17671112; http://dx.doi.org/10.1158/1078-0432.CCR-07-0632.
18. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91:1940-9; PMID:10564678; http://dx.doi.org/10.1093/jnci/91.22.1940.
19. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: A multitarget approach to radiosensitization. Clin Cancer Res 2003; 9:3749-55; PMID:14506167.
20. Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 2005; 65:6967-75; PMID:16061682; http://dx.doi.org/10.1158/0008-5472.CAN-05- 1304.
21. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 2010; 126:1216-25; PMID:19662650.
22. Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, et al. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 2005; 96:911-7; PMID:16367912; http://dx.doi.org/10.1111/j.1349-7006.2005.00125.x.
23. Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 2003; 79:973-80; PMID:14713575; http://dx.doi.org /10.1080/09553000310001626135.
24. Matsumoto Y, Machida H, Kubota N. Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res 2005; 46:215-21; PMID:15988140; http://dx.doi.org/10.1269/jrr.46.215.
25. Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene 2008; 27:5567-77; PMID:18504430; http://dx.doi.org/10.1038/onc.2008.172.
26. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68:2850-60; PMID:18413753; http://dx.doi.org/10.1158/0008-5472.CAN-07-5256.
27. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: A small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008; 10:R33; PMID:18430202; http://dx.doi.org/10.1186/bcr1996.
28. Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res 2012; 32:2551-61; PMID:22753713.
29. Chatterjee M, Andrulis M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, et al. The PI3K/Akt signalling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2012; PMID:23065523.
30. Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer 2012; 76:26-31; PMID:21996088; http://dx.doi.org/10.1016/j. lungcan.2011.09.011.
31. Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, et al. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One 2012; 7:e35436; PMID:22523597; http://dx.doi.org/10.1371/journal. pone.0035436.
32. Niewidok N, Wack LJ, Schiessl S, Stingl L, Katzer A, Polat B, et al. Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. Transl Oncol 2012; 5:356-69; PMID:23066444.
33. Stingl L, Niewidok N, Müller N, Selle M, Djuzenova CS, Flentje M. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α. Strahlenther Onkol 2012; 188:507-15; PMID:22441439; http://dx.doi.org/10.1007/s00066-012-0080-9.
34. Schilling D, Bayer C, Li W, Molls M, Vaupel P, Multhoff G. Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1α. PLoS One 2012; 7:e31110; PMID:22347438; http://dx.doi.org/10.1371/journal.pone. 0031110.
35. Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010; 102:1578-91; PMID:20502461; http://dx.doi.org/10. 1038/sj.bjc.6605683.
36. Terasima T, Tolmach LJ. Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 1961; 190:1210-1; PMID:13775960; http://dx.doi.org/10.1038/1901210a0.
37. Biade S, Stobbe CC, Chapman JD. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res 1997; 147:416-21; PMID:9092920; http://dx.doi.org/10.2307/3579497.
38. Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, Nalabothula NR, et al. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther 2011; 10:1194-206; PMID:21566061; http://dx.doi.org/10.1158/1535-7163.MCT-11-0094.
39. Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, et al.; Australian Prostate Cancer BioResource. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18:3562-70; PMID:22573351; http://dx.doi.org/10.1158/1078-0432. CCR-12-0782.
40. Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X, et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep 2012; 28:2247-54; PMID:23027394.
41. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63:8984-95; PMID:14695217.
42. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005; 65:11565-71; PMID:16357166; http://dx.doi.org/10.1158/0008-5472.CAN-05-3441.
43. Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, Deng H, et al. High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 2008; 71:1591-9; PMID:18640502; http://dx.doi.org/10.1016/j.ijrobp.2008.04.025.
44. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiat Res 1984; 99:73-84; PMID:6739728; http://dx.doi.org/10.2307/3576448.
45. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008; 14:5142-9; PMID:18698032; http://dx.doi.org/10.1158/1078-0432.CCR-07-4072.